RedPath Integrated Pathology
Interpace Dx Reaches Deal to Restructure Debt
As part of the deal with an institutional investor, Interpace's royalty and milestone obligations will also be terminated.
PDI Acquires MDx Firm RedPath Integrated Pathology
NEW YORK (GenomeWeb News) – PDI today announced it will buy molecular diagnostics company RedPath Integrated Pathology for more than $23 million in cash and stock.
RedPath Inks Contract with MultiPlan for Pancreatic Cancer Test
NEW YORK (GenomeWeb News) – RedPath Integrated Pathology today announced the execution of an agreement with preferred provider organization MultiPlan for RedPath's PathFinder TG test for pancreatic cancer.
ExonHit, RedPath Terminate Acquisition Deal
The deal was abandoned after the two companies could not reach new terms and conditions following a Medicare contractor's decision to cover only one of RedPath's tests.
ExonHit Shareholder Meeting on RedPath Buy Likely Delayed
ExonHit said that it anticipates a lack of quorum to vote on the acquisition, which last week hit a snag on the news that Medicare may drop RedPath's pancreatic cancer test.
Apr 27, 2010
Apr 26, 2010